Progressive Supranuclear Palsy clinical trials

Explore recruiting progressive supranuclear palsy clinical trials.

Recruiting progressive supranuclear palsy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Progressive Supranuclear Palsy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, Phase 2 study to assess the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) to slow the disease progression of progressive supranuclear palsy (PSP) PROSPER

Italy, France, Poland, Germany, Portugal, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Spain, Germany, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2b/3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)

Bulgaria, Austria, Netherlands, Sweden, Belgium, Spain +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension

Netherlands, Germany, Spain, Italy, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

ASSESSMENT OF THE BRAIN DEPOSIT OF TAU 4R DETECTED BY BRAIN PET WITH 18F-PI2620 IN PROGRESSIVE SUPRANUCLEAR PALSY COMPARED TO CONTROLS WITHOUT NEURODEGENERATIVE TAUOPATHY 4R: A CLINICAL TRIAL

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Quantification tools for a novel tau PET marker in a rare neurological disease: 18F-PI-2620 in progressive supranuclear palsy

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Progressive Supranuclear Palsy trials by city

Progressive Supranuclear Palsy in Toronto Progressive Supranuclear Palsy in Vancouver Progressive Supranuclear Palsy in Montreal Progressive Supranuclear Palsy in Calgary Progressive Supranuclear Palsy in Edmonton Progressive Supranuclear Palsy in Ottawa Progressive Supranuclear Palsy in Winnipeg Progressive Supranuclear Palsy in Quebec City Progressive Supranuclear Palsy in Hamilton Progressive Supranuclear Palsy in Kitchener Progressive Supranuclear Palsy in London Progressive Supranuclear Palsy in Halifax Progressive Supranuclear Palsy in New York Progressive Supranuclear Palsy in Los Angeles Progressive Supranuclear Palsy in Chicago Progressive Supranuclear Palsy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease